Percio S Gulko - Rheumatology | Icahn School of Medicine

Biography

Specialties

Rheumatology

Multi-Disciplinary Training Area

Disease Mechanisms and Therapeutics (DMT), Immunology [IMM]

Research

The Gulko Lab works on identifying new genes involved in the regulation of arthritis severity and joint damage. These new genes have the potential to become new prognostic biomarkers and new targets for more effective therapies for Rheumatoid Arthritis (RA) and other autoimmune diseases.

Education

MD, UCLA-University of California Los Angeles

Internship, Internal Medicine, Porto Alegre (BRAZIL) Medical School

Residency, Internal Medicine, Medical College of Georgia

Fellowship, Rheumatology, Porto Alegre (BRAZIL) Medical School

Fellowship, Rheumatology, National Cancer Institute, NIH

Fellowship, Rheumatology, Columbia University Medical Center-Psychiatry GME

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Gulko during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

TEK Systems

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Gulko during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

TEK Systems

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.